PROTAC RIPK degrader-2

• CAS Number:

  1801547-16-9

• UNSPSC Description:

  PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes[1][2].

• Target Antigen:

  PROTACs; RIP kinase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;PROTAC

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/protac-ripk-degrader-2.html

• Purity:

  99.48

• Solubility:

  DMSO : 150 mg/mL (ultrasonic)

• Smiles:

  CC1=C(SC=N1)C2=CC=C(CNC([C@H]3N(C([C@H](C(C)(C)C)NC(COCCOCCOCCOCCOC4=CC5=C(C(NC6=CC=C(SC=N7)C7=C6)=CC=N5)C=C4S(C(C)(C)C)(=O)=O)=O)=O)C[C@H](O)C3)=O)C=C2

• Molecular Weight:

  1060.31

• References & Citations:

  [1]Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7.|[2]Wang C, et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported